Prospective associations of psychedelic treatment for co-occurring alcohol misuse and posttraumatic stress symptoms among United States Special Operations Forces Veterans

Military Psychology, Journal Year: 2023, Volume and Issue: 36(2), P. 184 - 191

Published: Feb. 1, 2023

This study evaluated prospective associations of ibogaine and 5-MeO-DMT treatment for risky alcohol use post-traumatic stress disorder (PTSD) symptoms among United States (US) Special Operations Forces Veterans (SOFV). Data were collected during standard clinical operations at pre-treatment 1-month (1 m), 3-months (3 6-months (6 m) post-treatment in an program Mexico. Of the 86 SOFV that completed treatment, 45 met criteria (mean age = 44; male 100%; White 91%). There was a significant reduction from (M 7.2, SD 2.3) to 1 m 3.6; 3.5) post-treatment, which remained reduced through 6 4.0; 2.9; p < .001, partial eta squared .617). At m, 24% abstinent, 33% non-risky drinking, 42% drinkers. 16% 31% 53% no differences between responders (abstinent/non-risky drinkers) non-responders (risky demographics/clinical characteristics. However, there very large PTSD symptom (p .01, d −3.26) cognitive functioning change −0.99). Given these findings, future trials should determine whether psychedelic-assisted therapy holds promise individuals with complex trauma misuse who have not been successfully treated traditional interventions.

Language: Английский

---

Evaluation of Kratom Opioid Derivatives as Potential Treatment Option for Alcohol Use Disorder

Frontiers in Pharmacology, Journal Year: 2021, Volume and Issue: 12

Published: Nov. 3, 2021

Background and Purpose: Mitragyna speciosa extract kratom alkaloids decrease alcohol consumption in mice at least part through actions the δ-opioid receptor (δOR). However, most potent opioidergic alkaloid, 7-hydroxymitragynine, exhibits rewarding properties hyperlocomotion presumably due to preferred affinity for mu opioid (µOR). We hypothesized that like paynantheine speciogynine with reduced µOR potency could provide a starting point developing opioids an improved therapeutic window treat use disorder. Experimental Approach: characterized paynantheine, speciociliatine, four novel kratom-derived analogs their ability bind activate δOR, µOR, κOR. Select were assessed behavioral assays male C57BL/6N WT δOR knockout mice. Key Results: Paynantheine (10 mg∙kg −1 , i.p.) produced aversion limited conditioned place preference (CPP) paradigm but did not produce CPP additional conditioning sessions. robust antinociception block morphine-induced hyperlocomotion. Yet, 10 30 doses (i.p.), counteract morphine CPP. 7-hydroxypaynantheine 7-hydroxyspeciogynine displayed relative 7-hydroxymitragynine vitro dose-dependently decreased voluntary KO has maximally tolerated dose of (s.c.) which it significant neither alter general locomotion nor induce noticeable seizures. Conclusion Implications: Derivatizing goal enhancing reducing off-target effects pathway develop lead compounds disorder window.

Language: Английский

---

Racial/ethnic differences in prevalence of hallucinogen use by age cohort: Findings from the 2018 National Survey on Drug Use and Health

Journal of Psychedelic Studies, Journal Year: 2021, Volume and Issue: 5(2), P. 69 - 82

Published: July 15, 2021

Abstract Background Few studies have assessed the epidemiology of hallucinogenic substance use among racial and ethnic groups varying age cohorts. Use psychedelic substances may differ people color (POC), due to factors such as stigma discriminatory drug enforcement practices against POC. The lack inclusion POC in research further underscores importance identifying differences racial/ethnic Methods Data from 2018 National Survey on Drug Health (NSDUH) was used for this analysis ( N = 56,313, unweighted), representative non-institutionalized U.S. population. Proportions lifetime hallucinogen by race/ethnicity were compared. past year rates compared examine cohort. Results Approximately 15.9% population over 12 had a at some point their 2.0% year. Lifetime most prevalent non-Hispanic White multi-racial individuals, while Black/African Americans reported lowest use. also highest proportions 12–34 olds, individuals 35–49 olds. Hispanic higher 12–17 cohort, but lower 26–49 old 12–25 50+ older cohorts Limitations is cross-sectional self-reported. “Race” social construction subject change time, NSDUH ethnoracial categories are limited. Institutionalized populations not included study. Conclusions Significant observed. Findings work inform education, interventions, therapeutic research.

Language: Английский

---

The Safety and Efficacy of Psychedelic-Assisted Therapies for Older Adults: Knowns and Unknowns

American Journal of Geriatric Psychiatry, Journal Year: 2022, Volume and Issue: 31(1), P. 44 - 53

Published: Sept. 6, 2022

Language: Английский

---

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 30, 2025

Abstract Background and aims This is the first systematic review of extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco (TUD) other substance disorders (SUD). We aimed to summarise evidence efficacy AUD, TUD, SUD; evaluate its quality; offer recommendations research. Methods was a prospectively registered narrative open‐label, randomised controlled trials (RCT), observational studies d‐lysergic acid diethylamide (LSD), mescaline, psilocybin, ayahuasca, ketamine, ibogaine 3,4‐methylenedioxymethamphetamine (MDMA). Eligible had SUD outcome measures including craving, use, relapse, remission. Study quality evaluated using Cochrane Collaboration Risk Bias (RoB), RoB in Non‐randomised Studies Interventions tool. Certainty RCTs judged Grading Recommendations, Assessment, Development, Evaluations (GRADE) Findings 37 (2035 participants) were reviewed: LSD (14; n = 1047); mescaline (1; 7); psilocybin (4; 135); ayahuasca (3; 101); ketamine (10; 579); (5; 166); MDMA 14). There no serious adverse events reported any study. A two‐centre, placebo‐controlled, phase 2 superiority RCT double‐blind, four‐arm, placebo‐controlled AUD yielded best efficacy. Progression support 3 secured from an open‐label study TUD nine cannabis disorder, cocaine opioid (all with high‐RoB low‐GRADE certainty). Conclusions Psilocybin‐assisted appears have among treatments alcohol, tobacco, disorders. Future research should report safety events; screen person‐level characteristics indicating that contraindicated; strive mitigate blinding participants interventions; factorial designs drug psychotherapy trials; build consensus field‐specific Core Outcome Set.

Language: Английский

---